New Drugs Approval Timing In Italy (2015-2017)

Abstract

A659that contain both pharmaceutical and non-pharmaceutical schemes was calculated, and non-pharmaceutical expenditure items were identified and subtracted to produce a total pharmaceutical and non-pharmaceutical expenditure estimates and calculate their relative proportions. Results: For non-high-tech medicine, total expenditure decreased from € 1.66bn in 2012 to € 1.4bn in 2015 (15.7% decreases). For non-pharmaceutical items reimbursed under PCRS, the decrease in expenditure during this period was 0.68m (< 0.5% decrease). In 2015, total expenditure on nonpharmaceutical products reimbursed under PCRS was € 173m. ConClusions: Since the impact of the economic recession, the total cost of medicines reimbursed in Ireland has decreased. The decrease in expenditure, at a time of increasing demand, was supported by the introduction of mandatory rebates for innovative pharmaceutical medicines. This analysis shows that for non-pharmaceutical items, expenditure reductions over this period were not proportional.